Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
How to buy Vertex Pharmaceuticals stock
Learn how to easily invest in Vertex Pharmaceuticals stock.
Vertex Pharmaceuticals Inc is a biotechnology business based in the US. Vertex Pharmaceuticals shares (VRTX) are listed on the NASDAQ and all prices are listed in US Dollars. Vertex Pharmaceuticals employs 3,900 staff and has a trailing 12-month revenue of around $8.4 billion.
How to buy shares in Vertex Pharmaceuticals
- Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – VRTX – and research it before deciding if it's a good investment for you.
- Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
- Check in on your investment. Optimize your portfolio by tracking your stock.
What's in this guide?
- VRTX shares summary
- Compare share dealing platforms
- Is VRTX stock a buy or sell?
- Stock performance over time
- Is VRTX suitable for ethical investing?
- Are VRTX shares over-valued?
- Vertex Pharmaceuticals's financials
- How volatile are VRTX shares?
- Does Vertex Pharmaceuticals pay a dividend?
- Have VRTX shares ever split?
- Other common questions
Vertex Pharmaceuticals stock price (NASDAQ: VRTX)Use our graph to track the performance of VRTX stocks over time.
Vertex Pharmaceuticals shares at a glance
|Latest market close||$297.43|
|52-week range||$176.36 - $305.95|
|50-day moving average||$287.24|
|200-day moving average||$261.76|
|Wall St. target price||$310.54|
|Dividend yield||$0 (0%)|
|Earnings per share (TTM)||$12.21|
Buy Vertex Pharmaceuticals shares from these brokeragesCompare special offers, low fees and a wide range of types of investments among top trading platforms.
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy Vertex Pharmaceuticals stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Vertex Pharmaceuticals price performance over time
|1 week (2022-09-27)||4.46%|
|1 month (2022-09-02)||5.83%|
|3 months (2022-07-01)||3.52%|
|6 months (2022-04-01)||11.75%|
|1 year (2021-10-01)||64.92%|
|2 years (2020-10-02)||14.05%|
|3 years (2019-10-04)||72.50%|
|5 years (2017-10-04)||95.02%|
Is Vertex Pharmaceuticals stock undervalued or overvalued?
Valuing Vertex Pharmaceuticals stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Vertex Pharmaceuticals's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Vertex Pharmaceuticals's P/E ratio
Vertex Pharmaceuticals's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 24x. In other words, Vertex Pharmaceuticals shares trade at around 24x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
Vertex Pharmaceuticals's PEG ratio
Vertex Pharmaceuticals's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.3979. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Vertex Pharmaceuticals's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Vertex Pharmaceuticals's EBITDA
Vertex Pharmaceuticals's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $3.3 billion.
The EBITDA is a measure of a Vertex Pharmaceuticals's overall financial performance and is widely used to measure a its profitability.
Vertex Pharmaceuticals financials
|Revenue TTM||$8.4 billion|
|Operating margin TTM||37.59%|
|Gross profit TTM||$3.6 billion|
|Return on assets TTM||14.11%|
|Return on equity TTM||30.24%|
|Market capitalisation||$74.3 billion|
TTM: trailing 12 months
Vertex Pharmaceuticals's environmental, social and governance track record
Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like Vertex Pharmaceuticals.
When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.
Vertex Pharmaceuticals's total ESG risk score
Total ESG risk: 30.84
Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and Vertex Pharmaceuticals's overall score of 30.84 (as at 01/01/2019) is nothing to write home about – landing it in it in the 44th percentile of companies rated in the same sector.
ESG scores are increasingly used to estimate the level of risk a company like Vertex Pharmaceuticals is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).
Vertex Pharmaceuticals's environmental score
Environmental score: 5.65/100
Vertex Pharmaceuticals's environmental score of 5.65 puts it squarely in the 8th percentile of companies rated in the same sector. This could suggest that Vertex Pharmaceuticals is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.
Vertex Pharmaceuticals's social score
Social score: 24.22/100
Vertex Pharmaceuticals's social score of 24.22 puts it squarely in the 8th percentile of companies rated in the same sector. This could suggest that Vertex Pharmaceuticals is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.
Vertex Pharmaceuticals's governance score
Governance score: 12.46/100
Vertex Pharmaceuticals's governance score puts it squarely in the 8th percentile of companies rated in the same sector. That could suggest that Vertex Pharmaceuticals is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.
Vertex Pharmaceuticals's controversy score
Controversy score: 2/5
ESG scores also evaluate any incidences of controversy that a company has been involved in. Vertex Pharmaceuticals scored a 2 out of 5 for controversy – the second-highest score possible, reflecting that Vertex Pharmaceuticals has, for the most part, managed to keep its nose clean.
Environmental, social, and governance (ESG) summary
|Total ESG score||30.84|
|Total ESG percentile||44|
|Environmental score percentile||8|
|Social score percentile||8|
|Governance score percentile||8|
|Level of controversy||2|
Vertex Pharmaceuticals share dividends
We're not expecting Vertex Pharmaceuticals to pay a dividend over the next 12 months.
Have Vertex Pharmaceuticals's shares ever split?
Vertex Pharmaceuticals's shares were split on a 2:1 basis on 24 August 2000. So if you had owned 1 share the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your Vertex Pharmaceuticals shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for Vertex Pharmaceuticals shares which in turn could have impacted Vertex Pharmaceuticals's share price.
Vertex Pharmaceuticals share price volatility
Over the last 12 months, Vertex Pharmaceuticals's shares have ranged in value from as little as $176.36 up to $305.95. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Vertex Pharmaceuticals's is 0.4475. This would suggest that Vertex Pharmaceuticals's shares are less volatile than average (for this exchange).
Vertex Pharmaceuticals overview
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 6 years of age or older who have at least one F508del mutation. Its pipeline includes VX-864 for the treatment of AAT deficiency, which is in Phase 2 clinical trial; VX-147 for the treatment of APOL1-mediated focal segmental glomerulosclerosis, or FSGS, and other serious kidney diseases which is in Phase 2 clinical trial; VX- 880, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-548, a NaV1. 8 inhibitor for treatments of acute, neuropathic, musculoskeletal pain which is in Phase 2 clinical trial; and CTX001 for the treatment severe SCD and TDT which is in Phase 3 clinical trial. The company sells its products primarily to specialty pharmacy and specialty distributors in the United States, as well as specialty distributors and retail chains, and hospitals and clinics internationally. It has collaborations with Affinia Therapeutics, Inc. ; Arbor Biotechnologies, Inc.
Vertex Pharmaceuticals in the news
Stock Market Holds Morning Gains, Oil and Gas Play Breaks Out
Stock Market Posts Second Day Of Big Gains, Dow Adds 700 Points
3 Revolutionary Stocks I'd Buy Right Now Without Hesitation
Frequently asked questionsWhat percentage of Vertex Pharmaceuticals is owned by insiders or institutions?
Currently 0.229% of Vertex Pharmaceuticals shares are held by insiders and 94.367% by institutions. How many people work for Vertex Pharmaceuticals?
Latest data suggests 3,900 work at Vertex Pharmaceuticals. When does the fiscal year end for Vertex Pharmaceuticals?
Vertex Pharmaceuticals's fiscal year ends in December. Where is Vertex Pharmaceuticals based?
Vertex Pharmaceuticals's address is: 50 Northern Avenue, Boston, MA, United States, 02210 What is Vertex Pharmaceuticals's ISIN number?
Vertex Pharmaceuticals's international securities identification number is: US92532F1003 What is Vertex Pharmaceuticals's CUSIP number?
Vertex Pharmaceuticals's Committee on Uniform Securities Identification Procedures number is: 92532F100
More guides on Finder
Alternatives to Webull
Looking for a discount broker like Webull that offers something different? Here are some of the top alternatives to consider.
Best renewable energy stocks for 2022
Here are the best renewable energy stocks that should be on your radar to help you grow your green portfolio
Here are 6 manganese stocks that should be on your radar as EV batteries create new demand.
The best dividend stocks for 2022
Our list of 10 dividend stocks to watch in 2022.
How to buy YanGuFang International Group (YGF) stock when it goes public
Everything we know about the YanGuFang International Group IPO, plus information on how to buy in.
What are the FAANG stocks and how do you invest in them?
Looking to invest in tech? Here’s how to buy shares in the major tech companies, known as FAANG stocks.
How to buy soccer stocks
A simple guide to buying stocks in your favorite European soccer team.
How to buy Juventus stock
Steps to owning and managing JUVE, with 24-hour and historical pricing before you buy.
How to buy AS Roma stock
Steps to owning and managing ASR, with 24-hour and historical pricing before you buy.
How to buy Borussia Dortmund stock
Steps to owning and managing BVB, with 24-hour and historical pricing before you buy.
Ask an Expert